# Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

> **NCT00541359** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 54 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** bortezomib
- **DRUG:** topotecan hydrochloride
- **OTHER:** immunohistochemistry staining method
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00541359
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541359, "Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00541359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*